Patents by Inventor Christophe Hourioux

Christophe Hourioux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fusion proteins and use thereof for preparing vaccines
    Patent number: 10766930
    Abstract: An immunogenic fusion protein includes at least the following two peptides a) —on the C-terminal side, a first peptide constituted of: —the amino acid sequence of the protein S or the protein M of a human hepatitis B virus (HBV) isolate, which protein S or protein M is optionally deleted at the N-terminal end thereof, and b) —on the N-terminal side, a second peptide constituted of: —the sequence of amino acids of at least one transmembrane domain and the ectodomain of at least one protein of a Zika virus isolate selected from the envelope protein E or a fusion peptide including the envelope protein E and the protein prM.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: September 8, 2020
    Assignees: UNIVERSITE DE TOURS, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE—INSERM
    Inventors: Christophe Hourioux, Romuald Patient, Elodie Beaumont, Philippe Roingeard
  • NOVEL FUSION PROTEINS AND USE THEREOF FOR PREPARING VACCINES
    Publication number: 20190389912
    Abstract: An immunogenic fusion protein includes at least the following two peptides a) —on the C-terminal side, a first peptide constituted of: —the amino acid sequence of the protein S or the protein M of a human hepatitis B virus (HBV) isolate, which protein S or protein M is optionally deleted at the N-terminal end thereof, and b) —on the N-terminal side, a second peptide constituted of: —the sequence of amino acids of at least one transmembrane domain and the ectodomain of at least one protein of a Zika virus isolate selected from the envelope protein E or a fusion peptide including the envelope protein E and the protein prM.
    Type: Application
    Filed: June 16, 2017
    Publication date: December 26, 2019
    Inventors: Christophe HOURIOUX, Romuald PATIENT, Elodie BEAUMONT, Philippe ROINGEARD
  • Fusion proteins and use thereof for preparing hepatitis C vaccines
    Patent number: 8765143
    Abstract: An immunogenic fusion protein includes at least, on the C-terminal side, a first peptide composed of the S protein deleted of the transmembrane domain thereof located at the N-terminal end thereof, of a hepatitis B virus (HBV) isolate, and on the N-terminal side, a second peptide composed of the transmembrane domain and of the ectodomain of at least one envelope protein of a hepatitis C virus (HCV) isolate. A hybrid nucleic acid molecule encoding the fusion protein, and a vector including the hybrid nucleic acid molecule, a subviral particle including the fusion protein, an immunogenic composition including at least the fusion protein, or at least the hybrid nucleic acid molecule, or at least the subviral particle, and a cell line for the production of the fusion protein, or of the hybrid nucleic acid molecule, or of the subviral particle are described.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: July 1, 2014
    Assignee: Universite Francois Rabelais de Tours
    Inventors: Philippe Roingeard, Christophe Hourioux, Romuald Patient
  • NOVEL FUSION PROTEINS AND USE THEREOF FOR PREPARING HEPATITIS C VACCINES
    Publication number: 20110150921
    Abstract: An immunogenic fusion protein includes at least, on the C-terminal side, a first peptide composed of the S protein deleted of the transmembrane domain thereof located at the N-terminal end thereof, of a hepatitis B virus (HBV) isolate, and on the N-terminal side, a second peptide composed of the transmembrane domain and of the ectodomain of at least one envelope protein of a hepatitis C virus (HCV) isolate. A hybrid nucleic acid molecule encoding the fusion protein, and a vector including the hybrid nucleic acid molecule, a subviral particle including the fusion protein, an immunogenic composition including at least the fusion protein, or at least the hybrid nucleic acid molecule, or at least the subviral particle, and a cell line for the production of the fusion protein, or of the hybrid nucleic acid molecule, or of the subviral particle are described.
    Type: Application
    Filed: June 16, 2009
    Publication date: June 23, 2011
    Applicant: UNIVERSITE FRANCOIS RABELAIS DE TOURS
    Inventors: Philippe Roingeard, Christophe Hourioux, Romuald Patient